Financial ServicesFinanceOther Financial Services

Biogen Pharmachem Industries Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 30 filings·Updated 29 Sept 2026
Showing 10 of 30 filings.
29 Sept 20262 filings
AGM/EGMAGM

Biogen Pharmachem Industries AGM approves financial statements, director rotation, and statutory auditor appointment.

AGM details

  • Date 29 Sep 2026, 04:00 PM; VC/OAVM mode.
  • Record voting date 22 Sep 2026; e-voting window 26–28 Sep 2026.
  • Shareholders on record: 300,794; public attendees 32; promoter none.

Key resolutions

  • Adopt audited financial statements, directors’ and auditors’ reports for the year ended 31 March 2026.
  • Re-appointment of Kelash Bunkar as director by rotation.
  • Appointment of M/s Goenka Mehta & Associates as statutory auditors and remuneration to be fixed.

Voting results

  • Resolution 1 passed with 99.98% in favour; 0.02% against.
  • Resolution 2 passed with 99.64% in favour; 0.36% against.
  • Resolution 3 passed with 99.93% in favour; 0.07% against.

Dividend

  • No dividend proposed or declared at the AGM.

Director changes

  • No new appointments; rotation-based reappointment completed.

Auditor appointments

  • Statutory auditors appointed: M/s Goenka Mehta & Associates Chartered Accountants; remuneration to be fixed.

Material related party transactions

  • No material related party transactions disclosed.

Other material approvals

  • No other material approvals reported.
Filed 18:36View Source
AGM/EGMAGM

Biogen Pharmachem Industries holds 31st AGM via VC on 29 Sep 2026 with three ordinary resolutions approved

AGM Details

  • Date, time, mode: 29 September 2026 at 04:00 PM via VC/OAVM.
  • AGM duration: commenced 04:00 PM and concluded 04:20 PM.

Key Resolutions

  • Adoption of audited financial statements for year ended 31 March 2026 and reports.
  • Re-appointment of Mr. Kelash Bunkar as director, retiring by rotation.
  • Appointment of M/s Goenka Mehta & Associates as statutory auditors; remuneration to be fixed.

Voting Results

  • All resolutions passed by shareholders.
Filed 18:05View Source
17 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

Biogen Pharmachem Industries Limited — Trading Window closed from October 1, 2026 till 48 hours after the unaudited Q2 results declaration for the quarter ended September 30, 2026.

Biogen Pharmachem Industries Limited — Trading Window closed from October 1, 2026 till 48 hours after the unaudited Q2 results declaration for the quarter ended September 30, 2026.

Filed 16:47View Source
5 Aug 20262 filings
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Company declares no unutilised funds from past fundraising; no deviation reported

Utilisation status and deviation

  • Purpose: declaration of non-applicability due to zero unutilised funds.
  • Mode of fund raising: not disclosed.
  • Status: no unutilised funds; proceeds fully utilised.
  • Deviation: none; no variation to report.
Filed 16:06View Source
Board MeetingOutcome of Board Meeting

Biogen Pharmachem approves unaudited standalone quarterly results for quarter ended 30 June 2026

Financial results and audit status

  • Board approved unaudited standalone results for quarter ended 30 June 2026.
  • Audit Committee reviewed; statutory auditors carried out a limited review.
  • Total income for the quarter ended 30 June 2026: 44.34 lacs.
  • Net profit after tax for the quarter: 22.14 lacs.
  • Single segment; no separate segment results.
  • Paid-up equity share capital: 10,530.37 lacs.
  • Statutory auditors conducted limited review; no audit opinion expressed.
Filed 15:43View Source
7 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate confirms listing of dematerialised securities and cancellation of physical certificates; no demat requests received

Dematerialisation status

  • The securities have been listed on the stock exchanges.
  • Physical certificates were mutilated and cancelled; depository name substituted as registered owner.
  • No physical certificates were received for demat during the quarter.
Filed 15:20View Source
20 May 20263 filings
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rama Shiva Lease Finance Pvt Ltd

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 10:04View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rama Shiva Lease Finance Pvt Ltd

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 10:01View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Parichay Infrastructure Ltd

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 09:53View Source
1 Apr 20261 filing
Corp. ActionRecord Date

Biogen Pharmachem Industries Ltd - 531752 - Regulation 42 As Per SEBI LODR Intimation Of Record Date For Issuance Of Bonus Shares In The Proportion Of 1:6 I.E. 1 (One) New Equity Shares Of Rs.1/- Each For Every 6 (Six) Existing Equity Shares Of Rs.1/- Each Fully Paid Up And Held By The Members/ Beneficial Owner

Bonus Issue Record Date

  • Record date fixed as 15 May 2026 for bonus shares entitlement
  • Bonus shares issued at ratio of 1 new share per 6 existing shares
  • Bonus shares are equity shares of Rs.1 each fully paid
  • Issuance subject to shareholder approval via postal ballot and e-voting
Filed 11:41View Source
Showing 10 of 30 filings